Clinical trials: Multiple Myeloma in Relapse
Multiple Myeloma
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02605356
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 58 sites in United States, Australia and 9 more
- Sponsor
- Bayer
Leukemia, Lymphoma
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
RATIONALE: Giving chemotherapy drugs, such as fludarabine and melphalan, before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00008307
- Testing
- anti-thymocyte globulin, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Multiple Myeloma
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
In Phase I, patients will receive a combination of PS-341 (Velcade) and R115777 (Zarnestra) to determine the dose limiting toxicity (DLT).
- Trial name
- NCT00361088
- Testing
- PS-341, R11577
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00639002
- Testing
- Ruxolitinib 25 mg, Dexamethasone 40 mg
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
The purpose of this study is to induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially: 1) lymphoid and myeloid suppressive conditioning, 2)…
- Trial name
- NCT00089453
- Testing
- Dexamethasone, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.
- Conditions
- Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition
- Trial name
- IFM2014-01 (NCT03683277)
- Testing
- Ixazomib/Pomalidomide/Dexamethasone
- Where
- 28 sites in France
- Volunteers
- 26 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a…
- Trial name
- NCT05646836
- Testing
- Cevostamab, XmAb24306, Tocilizumab
- Where
- 13 sites in Australia, Denmark and 5 more
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00718601
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Geron Corporation
Relapsed Cancer, Refractory Multiple Myeloma
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
- Conditions
- Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- ISABELA (NCT05922501)
- Testing
- Isatuximab, Belantamab mafodotin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- CERVINO (NCT06158841)
- Testing
- Etentamig, Carfilzomib, Pomalidomide
- Where
- 166 sites in United States, Australia and 23 more
- Volunteers
- 421 people
- Sponsor
- AbbVie
Multiple Myeloma
Combination Study for High Risk Multiple Myeloma Patients
Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge.
- Trial name
- NCT03104270
- Testing
- Elotuzumab, Pomalidomide, Carfilzomib
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
This is a multicenter, open label, phase II randomized controlled study that will evaluate the efficacy of carfilzomib and dexamethasone in combination with cyclophosphamide in R/R MM patients.
- Trial name
- NCT03336073
- Testing
- Carfilzomib, Dexamethasone, cyclophosphamide
- Where
- 24 sites in Spain
- Volunteers
- 199 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma
An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D dual target CAR-T cells therapy in Patients with relapsed or refractory multiple myeloma
- Trial name
- NCT05325801
- Testing
- BMCA and GPRC5D dual target CAR-T cells(OriC321)
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of the study is to determine whether the combination of LDE225 (sonidegib) plus bortezomib is safe and effective in the treatment of relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT02254551
- Testing
- LDE225, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- SCRI Development Innovations, LLC
Myeloma Multiple
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma…
- Trial name
- NCT06245629
- Testing
- Bortezomib-bendamustine-melphalan
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Uppsala University
Multiple Myeloma
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM)…
- Trial name
- PKB115125 (NCT01428492)
- Testing
- GSK2110183, Bortezomib, Dexamethasone
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00530816
- Testing
- carfilzomib
- Where
- 30 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen